Latest news with #MyelodysplasticSyndrome
The Wire
3 days ago
- Health
- The Wire
Homeopathy's Triumph in ITP Treatment Offers New Hope for Blood Disorders
Indore (Madhya Pradesh) [India], July 16: A groundbreaking advancement in the treatment of blood disorders has emerged from Advanced Homoeo Health Center and Homeopathic Medical Research Pvt. Ltd., located at Geeta Bhawan, Indore. Under the leadership of Dr. A.K. Dwivedi, a senior homeopathic physician, member of the Scientific Advisory Board (CCRH), Ministry of AYUSH, Government of India, and Executive Council Member at Devi Ahilya Vishwavidyalaya, Indore, a revolutionary approach in homeopathy is offering renewed hope for patients battling rare and life-threatening conditions like Immune Thrombocytopenia (ITP), Aplastic Anemia, and Myelodysplastic Syndrome (MDS). A compelling success story has captured medical attention: 7-year-old Ayushmann Singh from Azamgarh, Uttar Pradesh, was diagnosed with severe ITP, with platelet levels critically low at just 8,000. After undergoing 12 months of continuous and evidence-based homeopathic treatment using advanced 50 millesimal potency, Ayushmann's platelet count dramatically increased to 2.3 lakhs, allowing him to return to a normal life—attending school, playing with friends, and enjoying a healthy childhood once again. 'This is more than a medical case—it is a message of hope,' said Dr. Dwivedi. 'In immune thrombocytopenia, the body's own immune system destroys its platelets. Our specialized approach in homeopathy offers not only symptom relief but addresses the patient's complete physical, emotional, and mental wellbeing.' Conventional treatments for ITP, such as long-term steroid use, immunoglobulins, or bone marrow transplants, often come with limited efficacy and severe side effects. In contrast, Dr. Dwivedi's patient-centered and scientifically grounded homeopathic protocols present a low-risk and sustainable alternative, especially in chronic and difficult-to-treat conditions. Widely acclaimed as 'Hope for the Bloodless', Dr. Dwivedi is known for his pioneering work in treating aplastic anemia and promoting anemia awareness through homeopathy. His efforts are inspiring growing interest in integrating homeopathy into mainstream healthcare conversations, especially for conditions with limited conventional solutions. The case of young Ayushmann has become a beacon for families seeking effective and gentle treatment paths, underscoring the potential of homeopathy not as an alternative, but as a serious and scientifically validated medical choice. (Disclaimer: The above press release comes to you under an arrangement with PNN and PTI takes no editorial responsibility for the same.). This is an auto-published feed from PTI with no editorial input from The Wire.
The Irish Sun
02-07-2025
- Health
- The Irish Sun
‘Please pray' plea from family of brave Donegal boy getting treatment in the Netherlands for rare blood disorder
A BRAVE young Donegal boy is undergoing a life-saving bone marrow transplant in the Netherlands today. Advertisement 2 Zach and his family have recently travelled to the Netherlands to seek treatment for his rare disorder Credit: Family Handout The syndrome, which affects a person's bone marrow, progresses into Acute Myeloid Leukaemia if left untreated. His only chance of survival lies in a bone marrow transplant, which is not available in Ireland. The devastating health diagnosis came only a year after his mother Patrice was diagnosed with AML. The mother-of-four, who underwent chemotherapy and a bone transplant for her illness, still receives treatment. Advertisement READ MORE ON IRISH NEWS The family have since received a tremendous amount of support from relatives, friends and the local community in the last year and a half. Zach and his family And today his grandmother, Kateleen Rodgers posted online asking for support. She said: 'Please pray for my grandson Zach McCrossan today who is having his bone marrow transplant in the Netherlands and for his mammy Patrice as well.' Advertisement Most read in The Irish Sun Zach's is expected to remain an inpatient at the Princess Máxima Center for Pediatric Oncology in Utrecht, Netherlands for at least three months. Following his awful diagnosis a GoFundMe was set up in April by the family to cover the costs of Zach's treatment. FUNDS RAISED Within 24 hours the campaign raised over €122,500, smashing their target of €3,500. In response the family posted on social media saying: "Whether you donated, organised a fundraiser, offered a lift, dropped off meals, minded our other children, shared advice, or simply sent a message of encouragement Advertisement "We have felt every bit of your love and kindness. "It's because of you... our incredible circle of family, friends, neighbours, and strangers with big hearts... "That we're able to be by Zach's side as he begins treatment in the Princess Máxima Center in Utrecht." 2 Donegal native Zach McCrossan was recently diagnosed with a rare blood disorder known as Myelodysplastic Syndrome Credit: Family Handout Advertisement
The Irish Sun
14-06-2025
- Health
- The Irish Sun
‘Our hearts are full of hope' – Irish family begins journey to the Netherlands for 4-year-old boy's rare treatment
AN IRISH family have started their journey to the Netherlands this morning to seek health treatment for the four-year-old boy. Zach McCrossan, based in St Johnston in Donegal, was recently diagnosed with high-risk Myelodysplastic Syndrome (MDS), a rare blood disorder that progresses to Acute Myeloid Advertisement 2 Zach has been diagnosed with a rare blood disorder Credit: Social media collects And his only chance of survival is a bone marrow transplant, which is not available in Ireland. He has now been referred to the Princess Máxima Center for Pediatric Oncology in Utrecht, The family were doubly shocked by the news of his diagnosis, as his mother, Patrice, was diagnosed with acute myeloid leukaemia in January 2024. The 32-year-old was rushed to Advertisement READ MORE ON HSE Unfortunately, the transplant wasn't as successful as the family had wished and Patrice now travels regularly to In April, the family launched a campaign to support Zach through his "critical treatment" as well as keep their "family together" during this difficult time. The campaign was launched with the goal of €3,500, and in 24 hours it had raised over €122,500 - smashing their initial target. The funds raised will go towards travel, Advertisement Most read in Health Exclusive Today, they began their journey to the airport after meeting their target for seeking Zach's treatment for his rare blood disorder. In awe of the support the family have received from their local community and beyond, they posted an update on "This morning, we left home and began our journey to the Netherlands with Zach. "As we make our way to the airport and step into this next chapter, our hearts are full of hope, of emotion, and of deep gratitude. Advertisement 'FELT EVERY BIT OF YOUR LOVE' "To every single person, near and far, who has supported us: thank you. "Whether you donated, organised a fundraiser, offered a lift, dropped off meals, minded our other children, shared advice, or simply sent a message of encouragement… "We have felt every bit of your love and kindness. "It's because of you... our incredible circle of family, friends, neighbours, and strangers with big hearts... Advertisement "That we're able to be by Zach's side as he begins treatment in the Princess Máxima Center in Utrecht." The family stated that they will regularly update their socials, GoFundMe campaign, and dedicated website on Zach McCrossan's progress over the coming weeks and months. 2 The family started their journey to the Netherlands to get Zach the treatment he requires Credit: Social media collects
Medscape
10-06-2025
- Health
- Medscape
Fast Five Quiz: Low-Risk Myelodysplastic Syndrome
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic stem cell disorders, each with varying levels of prognosis. Risk stratification is an important component of MDS; however, even lower-risk variants require a nuanced approach to management, and certain factors can further affect patient risk after diagnosis. What do you know about low-risk MDS? Check your knowledge with this quick quiz. Among the gene mutations identified that can influence the prognosis in MDS, SF3B1 mutation is strongly associated with favorable clinical outcomes. Other mutations such as such as TP53 , ASXL1 , EZH2 , ETV6 , and RUNX1 typically lead to poorer clinical outcomes. The National Comprehensive Care Network (NCCN) notes that combining analysis of these mutations in MDS with International Prognostic Scoring System (IPSS) can improve risk stratification beyond the strengths of the IPSS alone, which is standard practice in some treatment centers. Learn more about cytogenic studies for MDS. Data have shown that hypocellular bone marrow is one of several factors that predict good response to IST in patients with lower-risk MDS. The NCCN specifically recommends IST in select patients, generally those 'aged ≤60 years and with ≤5% marrow blasts, or those with hypocellular marrows, PNH clone positivity, or STAT-3 mutant cytotoxic T-cell clones.' Other factors associated with predicted benefit from IST include presence of dysplasia, young age (< 60 years), presence of HLA DR15, female sex, absence of ring sideroblasts, presence of trisomy 8, and relatively short duration of transfusion need. Learn more about hypocellular marrow in MDS. A study of patients with very low- and low-risk MDS found that mutations in three genes, IDH1 , IDH2 , and NPM1 , are more common among those patients with direct transformation to AML. NPM1 mutations are the most frequently-seen mutation in AML and are found in approximately 30%-35% of cases among adults. Mutations in ASXL1 , CBL , and TP53 were found to be associated with progression to higher-risk MDS but not with transformation to AML. Learn more about cytogenetics in MDS. According to a review published in JAMA , the median survival time for patients with low and very low risk MDS is 5.3 years and 8.8 years, respectively. This is consistent with other recent data. Collected data from the same JAMA review indicated that the median age for MDS diagnosis is approximately 70 years and is more common in males; chemotherapy and radiation therapy exposure are also reported significant risk factors. Further, the IPSS, revised-IPSS, and WHO classification-based prognostic scoring system are the most frequently used scoring systems for MDS risk. Learn more about MDS risk staging. Due to longer survival, patients with low-risk MDS might be given multiple red blood cell transfusions as part of their management (which could potentially lead to iron overload). To decrease iron overload, the NCCN recommends consideration of daily iron chelation with subcutaneous deferoxamine or oral deferasirox after > 20-30 transfusions. This approach is especially recommended for patients with lower-risk MDS or those who are potential candidates for transplantation. Learn more about iron chelation in MDS. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication.
Yahoo
05-06-2025
- Business
- Yahoo
Myelodysplastic Syndrome Competitive Landscape 2025: 262 Molecules in MDS Pipeline - A Peek into Future Therapeutics
Discover the competitive landscape of Myelodysplastic Syndrome (MDS) therapeutics. With 498,757 cases in 2024 and a slight increase by 2029, the report reveals a robust pipeline of 262 molecules and over 1,200 clinical trials. Uncover key market players, future catalysts, and strategic insights for effective market positioning. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Myelodysplastic Syndrome: Competitive Landscape" report has been added to reports provides a data-driven overview of the current and future competitive landscape in Myelodysplastic Syndrome Therapeutics. The analyst epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Myelodysplastic Syndrome (MDS) infection in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029. MDS is managed through a combination of supportive care, chemotherapy, and targeted therapies. The MDS pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase III development, and 87 assets in Phase II. Over the past decade, 1,229 clinical trials have been conducted in MDS. During the past decade, partnerships were most prevalent in North America and Europe. Report ScopeThe Myelodysplastic Syndrome Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease of the report include: Disease Landscape Disease Overview Epidemiology Overview Treatment Overview Marketed Products Assessment Breakdown by Mechanism of Action, Route of Administration Product Profiles with Sales Forecast Pricing and Reimbursement Assessment Annual Therapy Cost Time to Pricing and Time to Reimbursement Pipeline Assessment Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration Product Profiles with Sales Forecast Late-to-mid-stage Pipeline Drugs Phase Transition Success Rate and Likelihood of Approval Clinical Trials Assessment Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status Enrolment Analytics, Site Analytics, Feasibility Analysis Deals Landscape Mergers, Acquisitions, and Strategic Alliances by Region Overview of Recent Deals Commercial Assessment Key Market Players Future Market Catalysts Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the Myelodysplastic Syndrome Therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Myelodysplastic Syndrome Therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships. Key Topics Covered: 1 Preface2 Key Findings3 Disease Landscape3.1 Disease Overview3.2 Epidemiology Overview3.3 Treatment Overview4 Marketed Drugs Assessment4.1 Leading Marketed Drugs4.2 Overview by Mechanism of Action4.3 Overview by Molecule Type4.4 Product Profiles and Sales Forecast5 Pricing and Reimbursement Assessment5.1 Annual Cost of Therapy5.2 Time to Pricing and Reimbursement6 Pipeline Drugs Assessment6.1 Mid-to-late-stage Pipeline Drugs6.2 Overview by Development Stage6.3 Overview by Mechanism of Action6.4 Overview by Molecule Type6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)6.6 Therapy Area and Indication-specific PTSR and LoA7 Clinical Trials Assessment7.1 Historical Overview7.2 Overview by Phase7.3 Overview by Status7.4 Overview by Phase for Ongoing and Planned Trials7.5 Trials with Virtual Components7.6 Overview of Trials by Geography7.7 Single-Country and Multinational Trials by Region7.8 Top 20 Sponsors with Breakdown by Phase7.9 Top 20 Sponsors with Breakdown by Status7.10 Overview by Endpoint Status7.11 Overview by Race and Ethnicity7.12 Enrollment Data7.13 Top 20 countries for Trial Sites7.14 Top 20 Sites Globally7.15 Feasibility Analysis - Geographic Overview7.16 Feasibility Analysis - Benchmark Models8 Deals Landscape8.1 Mergers, Acquisitions, and Strategic Alliances by Region8.2 Recent Mergers, Acquisitions, and Strategic Alliances9 Commercial Assessment9.1 Key Market Players10 Future Market CatalystsFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
